Versed (midazolam)

Versed (midazolam) is filed as Benzodiazepine. The sections below restate public label fields stored for this profile.

Class
Benzodiazepine
Generic name
midazolam
Route
Intravenous / Intramuscular
Dosage forms
3 DOSAGE FORMS AND STRENGTHS NAYZILAM is supplied as a single-dose nasal spray unit containing 5 mg of midazolam in 0.1 mL solution. Single-dose nasal spray unit containing 5 mg midazolam per 0.1 mL solution. ( 3 )
Manufacturer
UCB, Inc.
Boxed warning
Yes

Approved uses

Preoperative sedation and anxiolysis Sedation for diagnostic and therapeutic procedures Induction of general anesthesia Continuous sedation of intubated ICU patients

How it works

Enhances the effect of GABA at the GABA-A receptor, producing sedation, anxiolysis, amnesia, and muscle relaxation.

Boxed warning

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death . Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions (5.1) and Drug Interactions (7.2) ] . The use of benzodiazepines, including NAYZILAM, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing NAYZILAM and throughout treatment, assess each patient's risk for abuse, misuse, and addiction [see Warnings and Precautions (5.2) ]. The continued use of benzodiazepines may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Although NAYZILAM is indicated only for intermittent use [see Indications and Usage (1) and Dosage and Administration (2) ] , if used more frequently than recommended abrupt discontinuation or rapid dosage reduction of NAYZILAM may precipitate acute withdrawal reactions, which can be life-threatening. For patients using NAYZILAM more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue NAYZILAM [see Warnings and Precautions (5.3) ]. WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS See full prescribing information for complete boxed warning. Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death ( 5.1 , 7.2 ) The use of benzodiazepines, including NAYZILAM, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Before prescribing NAYZILAM and throughout treatment, assess each patient's risk for abuse, misuse, and addiction ( 5.2 ). Although NAYZILAM is indicated only for intermittent use ( 1 , 2 ), if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of NAYZILAM may precipitate acute withdrawal reactions, which can be life-threatening. For patients using NAYZILAM more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue NAYZILAM ( 5.3 ).

Warnings and precautions

BLACK BOX WARNING: Respiratory depression and respiratory arrest, especially when used with opioids. Must be used in monitored settings with resuscitative equipment available. Individualize dosing.

Contraindications

Known hypersensitivity to benzodiazepines. Acute narrow-angle glaucoma.

Common side effects

Respiratory depression (Common); Apnea (With rapid IV push); Hypotension (Common); Hiccups (Common); Nausea/vomiting (Common); Oversedation (Dose-dependent); Amnesia (anterograde) (Very common — intended effect); Paradoxical agitation (Occasional, especially pediatric)

Adverse reactions

6 ADVERSE REACTIONS The following serious adverse reactions are discussed in more detail in other sections of the labeling: Risks from Concomitant Use with Opioids [see Warnings and Precautions (5.1) ] Abuse, Misuse, and Addiction [see Warnings and Precautions (5.2) ] Dependence and Withdrawal Reactions After Use of NAYZILAM More Frequently Than Recommended [see Warnings and Precautions (5.3) ] Risks of Cardiorespiratory Adverse Reactions [see Warnings and Precautions (5.4) ] CNS Depression from Concomitant Use with Other CNS Depressants or Moderate or Strong CYP3A4 Inhibitors [see Warnings and Precautions (5.5) ] Suicidal Behavior and Ideation [see Warnings and Precautions (5.6) ] Impaired Cognitive Function [see Warnings and Precautions (5.7) ] Glaucoma [see Warnings and Precautions (5.8) ] Neonatal Sedation and Withdrawal Syndrome [see Warnings and Precautions (5.9) ] Other Adverse Reactions [see Warnings and Precautions (5.10) ] The most common adverse reactions (≥5% in any NAYZILAM treatment group) were somnolence, headache, nasal discomfort, throat irritation, and rhinorrhea ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact UCB, Inc. at 1-844-599-2273 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. NAYZILAM was studied for the outpatient treatment of a single seizure cluster in 292 adult and adolescent patients with epilepsy (Study 1) [see Clinical Studies (14) ] . The study was conducted in two phases; an open-label Test Dose Phase followed by a double-blind, placebo-controlled, Comparative Phase. The mean age of patients enrolled in the Comparative Phase (N=201) was 33 years, 51% were female, and 95% were White. Table 2 lists the adverse reactions occurring in 2% or more of the NAYZILAM-treated patients and at a rate greater than the placebo-treated patients in the Comparative Phase of Study 1. Table 2: Adverse Reactions Adverse reactions that occurred within 2 days after NAYZILAM administration are included that Occurred in ≥2% of Patients (Any NAYZILAM) and Greater than Placebo in the Comparative Phase of Study 1 Body System/Adverse Reaction Placebo NAYZILAM Patients in Study 1 were permitted to take a second, open-label dose of NAYZILAM 5 mg between 10 minutes and 6 hours following the initial blinded dose of NAYZILAM 5 mg or placebo if they experience seizure recurrence or an incomplete resolution of the episode. The Placebo + NAYZILAM 5 mg and NAYZILAM 5 mg + 5 mg columns represent patients who received a second dose of NAYZILAM 5 mg and received a blinded initial dose of placebo or NAYZILAM 5 mg, respectively. NAYZILAM 5 mg Placebo + NAYZILAM 5 mg NAYZILAM 5 mg + 5 mg Any NAYZILAM Treatment Group N = 26 % N = 91 % N = 41 % N = 43 % N = 175 % Nervous System Somnolence 4 10 10 9 10 Headache 0 7 0 2 4 Dysarthria 0 2 2 2 2 Application Site Nasal Discomfort 8 5 7 16 9 Throat Irritation 0 2 2 7 3 Rhinorrhea 0 3 0 5 3 Product Taste Abnormal 0 4 0 0 2 Eye Disorders Lacrimation Increased 0 1 2 2 2 For patients who experienced a decrease in peripheral oxygen saturation in the Test Dose Phase of Study 1, the decreases were generally transitory. Two patients (one with a history of sleep apnea and one with intercurrent seizure) with decreases in peripheral oxygen saturation in the Test Dose Phase required therapeutic supplemental oxygen.

Dosage and administration

Procedural sedation: 0.5–2 mg IV over 2 minutes, titrate by 0.5–1 mg every 2–3 min (max 5–10 mg). ICU: 0.01–0.05 mg/kg/hr infusion. Must have resuscitation equipment available. DEA Schedule IV.

Drug interactions

CYP3A4 inhibitors (ketoconazole, itraconazole, erythromycin, protease inhibitors): markedly increased sedation. Opioids: synergistic respiratory depression (FDA boxed warning). Alcohol and other CNS depressants: additive effects. Flumazenil is the reversal agent.

Common questions

What is Versed approved to treat?

According to its FDA label, Versed (midazolam) is approved for: Preoperative sedation and anxiolysis. Sedation for diagnostic and therapeutic procedures. Induction of general anesthesia For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Versed?

Versed (midazolam) belongs to the Benzodiazepine class of medications.

What form does Versed come in?

The FDA label lists Versed (midazolam) as: 3 DOSAGE FORMS AND STRENGTHS NAYZILAM is supplied as a single-dose nasal spray unit containing 5 mg of midazolam in 0.1 mL solution. Single-dose nasal spray unit containing 5 mg midazolam per 0.1 mL solution. ( 3 ); intravenous / intramuscular route. Available strengths and packaging vary by manufacturer.

Does Versed have a Boxed Warning?

Yes. The FDA label for Versed (midazolam) carries a Boxed Warning. Excerpt: "WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depressi…" See the full FDA label for the complete warning. For medical advice, please talk to your prescriber or pharmacist.

How much does Versed cost?

Public CMS NADAC pricing for Versed (midazolam) is in the range Institutional: $2–$15 per vial (1 mg/mL or 5 mg/mL). Retail price varies by pharmacy, insurance, and manufacturer coupons.

Is Versed currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Versed (midazolam) in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Versed approved by the FDA?

The FDA record lists the approval date for Versed (midazolam) as 2019-05-17.

Who makes Versed?

The FDA label lists UCB, Inc. as a labeler/manufacturer of Versed (midazolam). Multiple firms may market generics of the same molecule.

How should Versed be stored?

The FDA label states: "16.2 Storage and Handling Do not open the blister packaging until ready to use. Do not test or prime before use. Do not use if the nasal spray unit appears damaged. Store at controlled room temperature 20°C to 25°C (68°F…" Follow the packaging insert for the authoritative guidance.

On this site

Other profiles with the same generic or brand name

Related medications in this class or category

Loading full data from Know Your Drugs Institute…